中国实用医药
中國實用醫藥
중국실용의약
China Practical Medical
2015年
35期
20-21
,共2页
胸腺肽α1%化疗%晚期恶性肿瘤
胸腺肽α1%化療%晚期噁性腫瘤
흉선태α1%화료%만기악성종류
Thymosin α1%Chemotherapy%Advanced malignant tumor
目的 观察胸腺肽α1联合化疗治疗晚期恶性肿瘤的临床效果.方法 80例晚期恶性肿瘤患者随机分成观察组和对照组, 每组35 例.对照组采用常规化疗, 观察组采用化疗联合注射用胸腺肽α1, 观察两组临床疗效.结果 观察组总有效率60.0%高于对照组的34.3%, 差异有统计学意义(P<0.05);治疗后, 观察组细胞免疫功能强于对照组(P<0.05).观察组治疗后卡氏评分比治疗前提高, 比较差异有统计学意义(P<0.05), 且与对照组比较差异有统计学意义(P<0.05).结论 胸腺肽α1联合化疗能改善患者的细胞免疫功能, 提高生活质量, 提高化疗有效率, 可在临床积极应用.
目的 觀察胸腺肽α1聯閤化療治療晚期噁性腫瘤的臨床效果.方法 80例晚期噁性腫瘤患者隨機分成觀察組和對照組, 每組35 例.對照組採用常規化療, 觀察組採用化療聯閤註射用胸腺肽α1, 觀察兩組臨床療效.結果 觀察組總有效率60.0%高于對照組的34.3%, 差異有統計學意義(P<0.05);治療後, 觀察組細胞免疫功能彊于對照組(P<0.05).觀察組治療後卡氏評分比治療前提高, 比較差異有統計學意義(P<0.05), 且與對照組比較差異有統計學意義(P<0.05).結論 胸腺肽α1聯閤化療能改善患者的細胞免疫功能, 提高生活質量, 提高化療有效率, 可在臨床積極應用.
목적 관찰흉선태α1연합화료치료만기악성종류적림상효과.방법 80례만기악성종류환자수궤분성관찰조화대조조, 매조35 례.대조조채용상규화료, 관찰조채용화료연합주사용흉선태α1, 관찰량조림상료효.결과 관찰조총유효솔60.0%고우대조조적34.3%, 차이유통계학의의(P<0.05);치료후, 관찰조세포면역공능강우대조조(P<0.05).관찰조치료후잡씨평분비치료전제고, 비교차이유통계학의의(P<0.05), 차여대조조비교차이유통계학의의(P<0.05).결론 흉선태α1연합화료능개선환자적세포면역공능, 제고생활질량, 제고화료유효솔, 가재림상적겁응용.
Objective To observe clinical effect by thymosin α1 combined with chemotherapy in the treatment of advanced malignant tumor.Methods A total of 80 patients with advanced malignant tumor were randomly divided into observation group and control group, with 35 cases in each group. The control group received conventional chemotherapy, and the observation group received thymosin α1 combined with chemotherapy. Their clinical effects were observed.Results The observation group had higher total effective rate as 60.0% than 34.3% of the control group, and the difference had statistical significance than the control group (P<0.05). After treatment, the observation group had stronger cellular immune function than the control group (P<0.05). The observation group had increased Karnofsky performance status after treatment, comparing with that before treatment, and the difference had statistical signficance (P<0.05), and its difference with the control group also had statistical significance (P<0.05).Conclusion Combination of thymosin α1 and chemotherapy can improve cellular immune function, life quality, and effectiveness of chemotherapy in patients. It can be actively applied.
